COMBINATION IMMUNOTOXIN/ANTINEOPLASTIC AGENT THERAPY FOR B-LINEAGE CANCER

摘要

A method is provided which utilizes highly potent and cell-type specific immunotoxins (IT) to systemically treat therapy refractory high risk ALL patients. The method of the present invention decreases the post BMT relapse rate by eliminating the radiation resistant and/or drug resistant residual leukemia burden. With slight modifications the method of the present invention should be generally applicable to preparation of other PAP-MoAb conjugates for treatment of other types of cancer or AIDS.